|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61P 35/04 | (2006.01) |
| A61K 38/1709 | (2013.01) | ||
| C12N 15/113 | (2010.01) | ||
| A61K 38/177 | (2013.01) | ||
| A61K 31/136 | (2006.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61K 31/4155 | (2006.01) | ||
| A61K 31/18 | (2013.01) | ||
| A61K 31/416 | (2006.01) | ||
| A61K 31/265 | (2013.01) | ||
| A61K 31/415 | (2013.01) | ||
| A61K 31/4164 | (2013.01) | ||
| A61K 31/47 | (2013.01) | ||
| A61K 31/5377 | (2013.01) | ||
| G01N 33/5743 | (2013.01) | ||
| G01N2500/10 | (2013.01) | ||
| A61K 31/136 | (2013.01) | ||
| A61K 31/4155 | (2013.01) | ||
| A61K 31/416 | (2013.01) | ||
| C07F 9/6506 | (2013.01) | ||
| A61K 31/4174 | (2013.01) | ||
| A61K 31/675 | (2013.01) | ||
| C07D 233/64 | (2013.01) | ||
| A61K 31/195 | (2013.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 35/04 | (2018.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 9/00 | (2018.01) |
| (11) | Patento numeris | 3626309 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 19189895.6 |
| Europos patento paraiškos padavimo data | 2013-08-13 | |
| (97) | Europos patento paraiškos paskelbimo data | 2020-03-25 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2023-03-08 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 201261682339 P | 2012-08-13 | US | |
| 201361784057 P | 2013-03-14 | US |
| (72) |
TAVAZOIE, Sohail , US
PENCHEVA, Nora, G. , US
|
| (73) |
The Rockefeller University ,
1230 York Avenue, New York, NY 10065,
US
|
| (54) | LXRBETA AGONIST FOR THE TREATMENT OF CANCER |
| LXRBETA AGONIST FOR THE TREATMENT OF CANCER |